AUTH/3747/2/23 - Anonymous complainant v Otsuka UK

Promotion of unlicensed medicines on LinkedIn

  • Received
    28 February 2023
  • Case number
  • Applicable Code year
  • Completed
    04 June 2024
  • Breach Clause(s)
  • Sanctions applied
    Undertaking received
  • Additional sanctions
  • Appeal
    No appeal

Case Summary

This case related to a LinkedIn post by Otsuka US that had been ‘liked’ by a senior UK employee of Astex Therapeutics Limited which was part of the wider Otsuka group. 

The outcome under the 2021 Code was: 

Breach of Clause 3.1

Promoting a medicine prior to the grant of its marketing authorisation

Breach of Clause 5.1

Failing to maintain high standards

Breach of Clause 6.1

Making a claim that was misleading by exaggeration

Breach of Clause 9.1

Failing to ensure members of staff are fully conversant with the Code and the relevant laws and regulations

Breach of Clause 14.4

Making an exaggerated claim that could not be substantiated

This summary is not intended to be read in isolation.
For full details, please see the full case report below.